Anusha S Thomas, M.D.
Department of Gastroenterology Hepatology and Nutrition, Division of Internal Medicine
About Dr. Anusha S Thomas
Dr. Thomas graduated with honors from Kasturba Medical College, Manipal University, India. She also received the gold medal in Pathology and Internal Medicine during her medical school training. Thereafter, she proceeded to complete Internal Medicine and Gastroenterology at the Houston Methodist Hospital, Houston, TX. Since joining The University of Texas MD Anderson Cancer Center as a clinical faculty in the Department of Gastroenterology, Hepatology and Nutrition, her practice has comprised of caring for patients with complications related to novel immunotherapy for advanced malignancies as well as colon cancer screening and prevention. She is a part of the immunotherapy toxicity working group in the department of Internal Medicine and has contributed to the MD Anderson institutional guideline for the same. She also is fascinated with the role of the human microbiome in gut inflammation. In particular, she is focused on studying and recognizing somatic mutations and consequent clonal expansions in normal colorectal epithelium as influenced by diet and the gut microbiome as some of the earliest events that set nascent cancers along particular trajectories that ultimately will provide for or thwart therapeutic interventions thereby potentially providing game-changing insights into early CRC. She strives to apply MD Anderson's core values of Caring, Integrity and Discovery every day, always placing her patients first so as to provide the best patient care and experience.
Present Title & Affiliation
Primary Appointment
Associate Professor, Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Medical Director- Endoscopy HALs, Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Medical Director, Department of Gastroenterology and Hepatology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2012 | Kasturba Medical College, Manipal University, IN, MD |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Gastroenterology, Underwood Center for Digestive Disorders - Houston Methodist Hospital, Houston, Texas |
| 2013-2016 | Clinical Residency, Internal Medicine Residency, Houston Methodist Hospital, Houston, Texas |
| 2011-2011 | Medical Electives, Cardiology, University of Minnesota Medical Center - Twin Cities, Minneapolis, Minnesota |
| 2011-2011 | Medical Electives, Pediatric Infectious Diseases, University of Minnesota Medical Center - Twin Cities, Minneapolis, Minnesota |
Licenses & Certifications
| 2019 | Texas Medical Board |
| 2019 | American Board of Internal Medicine-Gastroenterology |
| 2016 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Gastroenterology, Hepat,& Nutr, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2025
Other Professional Positions
Chief Fellow, Houston Methodist Hospital, Houston, TX, 2018 - 2019
GI Fellow, Houston Methodist Hospital, Houston, TX, 2016 - 2018
Internal Medicine Resident, Houston Methodist Hospital, Houston, TX, 2014 - 2016
Resident Intern, Houston Methodist Hospital, Houston, TX, 2013 - 2014
MCAT/SAT Instructor, The Princeton Review, Atlanta, GA, 2012 - 2013
Executive Administrative Assistant, National Resources Inc, Snellville, GA, 2011 - 2012
American College of Gastroenterology Educational Affairs Committee, Member, The University of Texas MD Anderson Cancer Center, Houston, Texas
Extramural Institutional Committee Activities
Member, ACG educational affairs committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Downstream Capacity Institutional Initiative: Capacity Management-Anesthesia Criteria Workgroup; Operations/Faculty Strategic Planning Workgroup, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Member, Credentials Committee of the Medical Staff (CCMS), The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, GHN Fellowship Core Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024
Member, UT-HIP Expert Panel: Use of PPIs in the Employee Drug Benefit Plan, UT Healthcare System, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, GHN Faculty Recruitment Search Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2022
Member, HAL Procedural Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, West Houston Quality and Safety Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2024
Liaison, Women and Minority Faculty Inclusion, The University of Texas MD Anderson Cancer Center, 2019 - 2021
Member, Division of Education & Training Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Institutional IOTOX Working Group, The University of Texas MD Anderson Cancer Center, 2019 - Present
Editorial Activities
Reviewer, Current Opinion of Gastroenterology Special Issue: Large Bowel, 2025 - Present
Reviewer, Current Cancer Therapy Reviews, 2021 - Present
Honors & Awards
| 2022 | ACG Governors Award for Excellence in Clinical Research, American College of Gastroenterology |
| 2022 | New and Mentee Reviewer Award, American Society for Gastrointestinal Endoscopy |
| 2015 | Regional and State Level American College of Physicians Oral Presentation Winner, American College of Physicians |
| 2009 - 2010 | Certificate of Merit for Academic Excellence, Final Year Part II MBBS University Examination |
| 2009 - 2010 | Gold Medal for Academic Excellence in Internal Medicine |
| 2008 - 2009 | Certificate of Merit for Academic Excellence, Final Year Part I MBBS University Examination |
| 2007 - 2008 | Gold Medal for Academic Excellence in Pathology |
| 2007 - 2008 | Certificate of Merit for Academic Excellence, Second MBBS University Examination |
| 2006 - 2008 | Sir Ratan Tata Trust Scholarship, Sir Ratan Tata Trust |
| 2006 - 2007 | Kassel Education Scholarship Award, University of Kassel |
| 2005 - 2007 | Bishop Scholarship Award, Bishop |
| 2005 - 2006 | Certificate of Merit for Academic Excellence, First MBBS University Examination |
| 2003 | Certificate of Merit, All India Secondary School Examination |
| 2003 | Dr. B. Vasantha Shetty Memorial Endowment, All Indian Secondary School Examination |
| 2003 | Sandeep Shetty Memorial Scholarship, Sandeep Shetty Memorial Endowment |
| 2003 | Srimathi Gangamma Ammananaya Memorial Endowment, Little Rock Indian School |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Endoscopic Management of Gastrointestinal Lesions. Conference. UT MD Anderson Cancer Center. Houston, Texas, US.
- 2023. Pancreatic irAEs. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
- 2023. Therapy Induced Colitis. Conference. CCSG Program. Houston, TX, US.
- 2022. Pancreatic irAEs. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
- 2019. The approach to a patient with dysphagia. Conference. UT MD Anderson Cancer Center. Houston, TX, US.
- 2019. Gastrointestinal Lymphoma - The New Mimic. Conference. Houston Methodist Hospital. Houston, TX, US.
- 2018. Non cirrhotic portal hypertension. Conference. Houston Methodist Hospital. Houston, TX, US.
- 2018. Hemobilia - evaluation and management. Conference. Houston Methodist Hospital. Houston, TX, US.
- 2017. The role of Endo FLIP in assessing GE junction distensibility. Conference. Houston Methodist Hospital. Houston, TX, US.
- 2017. CT enterography vs. capsule endoscopy for the evaluation of small bowel bleeding. Conference. Houston Methodist Hospital. Houston, TX, US.
- 2017. Acute liver failure secondary to lymphoma. Conference. Houston Methodist Hospital. Houston, TX, US.
- 2016. 59-Year-Old Man with Abdominal Pain. Conference. Houston Methodist Hospital. Houston, TX, US.
National Presentations
- 2025. Evaluating the Role of Pancreatic Enzyme Replacement Therapy (PERT) in ICI induced diarrhea management. Poster. Digestive Disease Week, US.
- 2025. Evaluating fecal elastase levels in the context of immune mediated diarrhea. Poster. Digestive Disease Week, US.
- 2025. Investigating the Relationship between Vitamin D Levels and Immune Mediated Colitis. Poster. Digestive Disease Week, US.
- 2025. The prognostic value of fecal calprotectin in predicting need for aggressive treatment and future disease remission among patients with immune checkpoint inhibitor colitis. Poster. Digestive Disease Week, US.
- 2025. Fecal transplantation improved patients’ reported outcome after immune checkpoint inhibitor colitis. Poster. Digestive Disease Week, US.
- 2025. Randomized Clinical Trial of Infliximab Versus Vedolizumab for Immune Checkpoint Inhibitor Related Colitis. Conference. Digestive Disease Week, US.
- 2025. First-Line Treatment of Fecal Microbiota Transplantation for Immune-Mediated Colitis. Conference. Digestive Disease Week, US.
- 2025. Risk factors and clinical course of inflammatory bowel disease patients undergoing cancer therapy. Poster. Digestive Disease Week, US.
- 2025. Clinical features and outcomes of immune-mediated gastroenteritis in cancer patients receiving immune-checkpoint inhibitors. Poster. Digestive Disease Week, US.
- 2025. Survival outcomes in patients with cancer and inflammatory bowel disease: Factors influencing mortality. Poster. Digestive Disease Week, US.
- 2025. “SEVERITY” OF IMMUNE CHECKPOINT INHIBITOR PANCREATITIS (ICIP): COMPARISON OFATLANTA CRITERIA (AC), COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE)GRADING OF PANCREATITIS (CTCAE-P), AND LIPASE ELEVATION (CTCAE-L). Poster. Digestive Disease Week, US.
- 2023. Type 3 Autoimmune Pancreatitis: Clinical Profile and Response to Steroids. Invited. AGA. Chicago, IL, US.
- 2022. IL12/23 Blockade Therapy for Refractory Immune-mediated Colitis: A Case Series from two centers. Conference. ACG. Charlotte, NC, US.
- 2022. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis: Clinical Profile and Natural History Based on Serial Pancreas Volumetry. Conference. AGA Institute Council. San Diego, CA, US.
- 2021. Symptomatic Type 3 auto- immune pancreatitis/immune checkpoint inhibitor pancreas injury (ICI-PI) leads to chronic pancreatic injury. Poster. Conference. APA 2021 52nd Annual Meeting. Miami, FL, US.
- 2021. Focused Expertise of IOTox GI Service Can Improve Quality of Clinical Care and Outcome of Immune Mediated Diarrhea/Colitis Among Inpatients: A Retrospective Review and Quality Improvement Project. Conference. ACG 2021 Annual Meeting. Las Vegas, NV, US.
- 2021. IL12/23 Blockade Therapy for Refractory Immune Checkpoint Inhibitor Colitis: A Case Series. Conference. ACG 2021 Annual Meeting. Las Vegas, NV, US.
- 2021. Microbiome Alteration via Fecal Microbiota Transplantation (FMT) Is Effective for Immune Checkpoint Inhibitor (ICI) Induced-Colitis (IMC) Refractory to Immunosuppressive Therapy. Conference. ACG 2021 Annual Meeting. Las Vegas, NV, US.
- 2021. Immune checkpoint inhibitor resumption is associated with better long term outcome in cancer patients. Poster. Conference. Digestive Disease Week 2021, US.
- 2021. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with immune-mediated diarrhea and colitis. Poster. Conference. Digestive Disease Week 2021, US.
- 2021. Clostridioides Difficile infections in cancer patients on immune checkpoint inhibitors. Oral Lecture. Conference. Digestive Disease Week 2021, US.
- 2021. Characteristics, treatment, and outcomes of CMV infection in patients treated with immune checkpoint inhibitors. Conference. Digestive Disease Week 2021, US.
- 2021. Clinical characteristics and outcomes of patients with positive celiac serology and cancer therapy exposure. Poster. Conference. Digestive Disease Week 2021, US.
- 2021. Incidence of Immune Checkpoint Inhibitor Related GI Toxicity in Patients with GI Luminal Malignancy and Outcomes after Treatment. Oral Lecture. Conference. Digestive Disease Week 2021, US.
- 2021. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in cancer patients: a multi-center study. Oral Lecture. Conference. Digestive Disease Week 2021, US.
- 2021. . Maintenance therapy reduces recurrence of immune-mediated colitis after resumption of immunotherapy in cancer patients. Poster of distinction. Conference. Digestive Disease Week 2021, US.
- 2015. Acyclovir resistant HSV meningo-encephalitis in an immunocompetent individual. Conference. ACP Associates Day 2015. Galveston, TX, US.
- 2014. Diarrhea in a transplant patient: Hepatitis E. Conference. ACP Associates Day 2014. Galveston, TX, US.
Formal Peers
- 2021. Approach to a patient with diarrhea. Visiting. Galveston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | Assessment of Patients with chronic loose stools following right-sided colectomy for colon cancer and the association with bile acid malabsorption (BAM) and small intestinal bacteria overgrowth (SIBO), using a novel intestinal fluid sampling device |
| Funding Source: | Texas Society of Gastrointestinal Endoscopy (TSGE) |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | The role of Vitamin D receptor mutations in patients with inflammatory bowel diseases in relation to Vitamin D deficiency and response to pharmacologic therapy |
| Funding Source: | Houston Methodist Hospital |
| Role: | Co-I |
| Date: | 2017 - 2018 |
| Title: | Retrospective analysis of use of anesthesia in IBD patients vs non IBD patients |
| Funding Source: | Houston Methodist Hospital |
| Role: | Co-I |
| Date: | 2015 - 2018 |
| Title: | The Effect of the Menstrual Cycle on IBD Symptoms |
| Funding Source: | Houston Methodist Hospital |
| Role: | Co-I |
| Title: | Cancer treatment-induced gastrointestinal tract toxicities - MD Anderson Cancer Center 20 Years Experience |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | PA18-0472 |
| Title: | Treatment of immune checkpoint inhibitor-related colitis within fliximab or vedolizumab: a randomized trial |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2019-0276 |
Selected Publications
Peer-Reviewed Articles
- Vemulapalli, V, Quirk, N, Wali, S, Natha, C, Chatterjee, A, Ahuja, R, Gupta, T, Rong, J, Gajagowni, S, Peddireddy, A, Jafri, F, Wang, Y, Thomas, AS. Investigating the relationship between vitamin D levels and immune-mediated colitis. Annals of Gastroenterology 39(3):344-351, 2026. e-Pub 2026. PMID: 42164601.
- Natha C, Colli Cruz C, Vemulapalli V, Sullivan A, Naz S, Ahuja R, Haque K, Zhou E, Haydel J, Quirk N, Wali S, Takigawa K, Prasad P, Peddireddy A, Shi K, Lu E, Lee AM, Julia Moura Nascimento Santos M, Junek K, Silva N, Pabani A, Philpott J, Thomas AS, Wang Y. Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapy. Eur J Gastroenterol Hepatol 38(6):670-677, 2026. e-Pub 2026. PMID: 41524591.
- Shatila, M, Cruz, CC, Varatharajalu, K, Urias Rivera, AC, Abdul-Baki, K, Takigawa, K, Gupta, T, Baerman, E, Lu, L, Jeong-Ah Lee, I, Salim, H, Menon, R, Sullivan, A, Vemulapalli, V, Natha, C, Khan, A, Grivas, PD, Faleck, DM, Dougan, M, Thomas, AS, Wang, Y. Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis. iGIE 5(2):136-144.e5, 2026. e-Pub 2026. PMID: 42394871.
- Cruz CC, Santos MJMN, Wali S, Mortan R, Ahuja R, Rong J, Gupta T, Lee IJ, Natha C, Vemulapalli V, Ngo S, Takigawa K, Varatharajalu K, Kennedy LB, Pabani A, Schneider BP, Kim KC, Shafi MA, Thomas AS, Wang Y. Efficacy of current therapeutic strategies for immune checkpoint inhibitor-related esophagitis. Ann Gastroenterol 39(2):228-237, 2026. e-Pub 2026. PMID: 41868882.
- Wali S, Patel RS, Santos MJMN, Chatterjee A, Fan SC, Ngo S, Gupta T, Baki KA, Heinzerling L, Schneider BJ, Bollin K, Philpott J, Thomas A, Wang Y. Isolated immune-mediated enteritis in patients treated with immune checkpoint inhibitor therapy. Ann Gastroenterol 39(2):262-269, 2026. e-Pub 2026. PMID: 41868875.
- Thomas, AS. Editorial. Current opinion in gastroenterology 42(1):1, 2026. e-Pub 2026. PMID: 41343255.
- Cruz, CC, Santos, MJ, Wali, S, Natha, C, Mortan, R, Ahuja, R, Rong, J, Gupta, T, Lee, IA, Vemulapalli, V, Ngo, S, Takigawa, K, Varatharajalu, K, Kim, KC, Bollin, KB, Champiat, S, Shafi, MA, Thomas, AS, Wang, Y. Beyond Proton Pump Inhibitors. Targeted oncology 21(1):103-115, 2026. e-Pub 2026. PMID: 41381800.
- Ahuja, R, Shatila, M, Shah, JS, Natha, C, Vemulapalli MDi, V, Mittal, N, Haydel, JM, Jeong-Ah Lee, I, Urias Rivera, AC, Cruz, CC, Schneider, BJ, Grover, S, Pabani, A, Thomas, AS, Wang, Y. Recent Abdominal Surgery as a Risk Factor for Unfavorable Immune-Mediated Colitis Outcomes. Gastro Hep Advances 5(1), 2026. e-Pub 2026.
- Shatila M, Wali S, Cruz CC, Takigawa K, Rivera ACU, Abdul-Baki K, Gupta T, Baerman E, Lu L, Lee IJ, Menon R, Salim H, Sullivan A, Vemulapalli V, Natha C, Khan A, Varatharajalu K, Champiat S, Reynolds KL, Kennedy LB, Tsai K, Thomas AS, Wang Y. Immune-mediated diarrhea and colitis with normal biochemical, endoscopic and histologic findings: a retrospective study. Ann Gastroenterol 39(1):79-87, 2026. e-Pub 2026. PMID: 41612986.
- Kuang AG, Shatila M, Shah JS, Mittal N, Naz S, Ebinama U, Iyer SP, Strati P, Shafi MA, Thomas AS, Zhang HC, Wang Y. Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy. Ther Adv Med Oncol 18:17588359261417635, 2026. e-Pub 2026. PMID: 41705138.
- Shatila M, Wang Y, Shirwaikar Thomas A. Colon chaos: when drugs turn against your gut. Curr Opin Gastroenterol 42(1):59-65, 2025. e-Pub 2025. PMID: 41198062.
- Shatila, M, Cruz, CC, Takigawa, K, Rivera, AU, Abdul-baki, K, Gupta, T, Baerman, E, Lu, L, Lee, IA, Menon, R, Sullivan, A, Vemulapalli, V, Natha, C, Salim, H, Khan, A, Varatharajalu, K, Johnson, DB, Kim, KC, Champiat, S, Thomas, AS, Wang, Y. Disease Outcomes in Immune-Mediated Colitis. JNCCN Journal of the National Comprehensive Cancer Network 23(9), 2025. e-Pub 2025. PMID: 40930146.
- Adames SM, Naz S, Dai J, Wang Y, Shirwaikar Thomas A. The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse Gastrointestinal Toxicities. J Clin Med 14(13), 2025. e-Pub 2025. PMID: 40649085.
- Shatila M, Devalaraju S, Takigawa K, Catinis C, Lee I, Baerman E, Ngo S, Mittal N, Glombicki S, Machado AP, Lu L, Aleem AS, Thompson J, Funchain P, Grover S, Zhang HC, Thomas AS, Wang Y. Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy. J Natl Compr Canc Netw 23(7):1-7, 2025. e-Pub 2025. PMID: 40533069.
- Shatila M, Sperling G, Machado AP, Vohra M, Baerman E, Toni EN, Torok HP, Zhao D, Zhou Y, Shafi MA, Thomas AS, Alasadi M, Wang Y. Helicobacter pylori infection negatively affects response of gastric cancer to immunotherapy. Ann Gastroenterol 38(3):262-269, 2025. e-Pub 2025. PMID: 40371204.
- Shatila M, Cruz CC, Lu L, Abdul-Baki K, Baerman E, Takigawa K, Rivera AU, Lee IJ, Ngo S, Sperling G, Aleem AS, Menon R, Sullivan A, Vemulapalli V, Natha C, Gupta T, Khan A, Mittal N, Coleman G, Salim H, Wali S, Varatharajalu K, Kim KC, Reddy SA, Grivas P, Thomas AS, Wang Y. The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor. Eur J Cancer 221:115405, 2025. e-Pub 2025. PMID: 40239400.
- Shah J, Caleb Urias Rivera A, Lee IJ, Takigawa K, Mathew A, Wu D, Lu E, Shatila M, Thomas AS, Zhang HC, Altan M, Zhao D, Xiao Q, Wang Y. The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity. Am J Clin Oncol 48(3):136-141, 2025. e-Pub 2025. PMID: 39473073.
- Shatila M, Eshaghi F, Cruz CC, Machado AP, Mathew A, Zhao D, Siddiqui BA, Thomas AS, Chari ST, Wang Y. Differential Disease Behavior of Immune-Mediated Colitis Among Different Types of Immune Checkpoint Inhibition. Target Oncol 20(2):339-347, 2025. e-Pub 2025. PMID: 40038186.
- Shatila M, Machado AP, Shah J, Rivera AU, Naz S, Glombicki S, Wali S, Lu E, Short N, Thomas AS, Zhang HC, Wang Y. Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events. Target Oncol 20(2):329-337, 2025. e-Pub 2025. PMID: 39904838.
- Pizuorno Machado, A, Adames, SM, Shatila, M, Aujla, P, Huey, RW, Wang, Y, Thomas, AS. Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer. Annals of Gastroenterology 38(1):72-79, 2025. e-Pub 2025. PMID: 39802282.
- Shatila, M, Takigawa, K, Lu, Y, Urias Rivera, AC, Mittal, N, Aleem, A, Ngo, S, Lu, E, Wu, D, Sperling, G, Naz, S, Schneider, BJ, Thomas, AS, Wang, Y. Predictive Value of FDG Uptake on PET for Future Immune Checkpoint Inhibitor-Mediated Colitis. Journal of Clinical Medicine 14(1), 2025. e-Pub 2025. PMID: 39797338.
- Shatila, M, Zhang, HC, Thomas, AS, Pizuorno Machado, A, Naz, S, Mittal, N, Catinis, C, Varatharajalu, K, Colli Cruz, C, Lu, E, Wu, D, Brahmer, JR, Carbonnel, F, Hanauer, S, Lashner, B, Schneider, BJ, Thompson, JA, Obeid, M, Farris, D, Wang, Y. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. Journal for immunotherapy of cancer 12(11), 2024. e-Pub 2024. PMID: 39542654.
- Wang Y, Abu-Sbeih H, Tang T, Shatila M, Faleck D, Harris J, Dougan M, Olsson-Brown A, Johnson DB, Shi C, Grivas P, Diamantopoulos L, Owen DH, Cassol C, Arnold CA, Warner DE, Alva A, Powell N, Ibraheim H, De Toni EN, Philipp AB, Philpott J, Sleiman J, Lythgoe M, Daniels E, Sandhu S, Weppler AM, Buckle A, Pinato DJ, Thomas AS, Qiao W. Novel endoscopic scoring system for immune mediated colitis: A multicenter Retrospective Study of 674 Patients. Gastrointest Endosc 100(2):273-282.e4, 2024. e-Pub 2024. PMID: 38272276.
- Shah J, Devalaraju S, Baerman E, Lee IJ, Takigawa K, Machado AP, Catinis C, Shatila M, Varatharajalu K, Shafi M, Lee HC, Strati P, Thomas A, Wang Y. Gastrointestinal Toxicities of Proteasome Inhibitor Therapy. J Cancer Res Clin Oncol 150(7):334, 2024. e-Pub 2024. PMID: 38969842.
- Wang, Y, Shatila, M, Catinis, C, Devalaraju, S, Glombicki, SE, Jeong-Ah Lee, I, Ngo, S, Takigawa, K, Lu, L, Mittal, N, Baerman, E, Aleem, A, Pizuorno Machado, A, Thomas, AS. The impact of proton-pump inhibitor use on the incidence and severity of gastrointestinal toxicity to checkpoint inhibition. Journal of Clinical Oncology 42(16):2657, 2024. e-Pub 2024.
- Shatila, M, Varatharajalu, K, Shen, SE, Herrera, M, Wang, XS, Thomas, AS, DuPont, HL, Wang, Y. Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis. Journal of Clinical Oncology 42(16):2517, 2024. e-Pub 2024.
- Machado, AP, Shaikh, AS, Saji, A, Shatila, M, Oliva, IG, Wang, Y, Thomas, AS. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer. Cancers 16(10), 2024. e-Pub 2024. PMID: 38791997.
- Shatila M, Eshaghi F, Thomas AR, Kuang AG, Shah JS, Zhao B, Naz S, Sun M, Fayle S, Jin J, Abudayyeh A, Sheshadri A, Palaskas NL, Franco-Vega MC, Gaeta MS, Thomas AS, Zhang HC, Wang Y. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Cancers (Basel) 16(2), 2024. e-Pub 2024. PMID: 38254858.
- Wang, Y, Shatila, M, Sperling, G, Pizuorno Machado, A, Vohra, MH, Baerman, E, De Toni, EN, Török, HP, Zhao, D, Zhou, Y, Shafi, MA, Thomas, AS, Alasadi, M. Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors. Journal of Clinical Oncology 42(3):277, 2024. e-Pub 2024.
- Thomas, AS, Abreo, M, Ahmed, AS, Rao Manikonda, SP, Eyada, M, Issac, AG, Abraham, FO, Jacob, JS, Wang, Y, Yedururi, S, Chari, ST. Immune Checkpoint Inhibitor-Induced Pancreatic Injury. Gastro Hep Advances 3(3):361-367, 2024. e-Pub 2024. PMID: 39131139.
- Wang, Y, Varatharajalu, K, Shatila, M, Junek, K, Ninoska, NN, Msaouel, P, Campbell, M, Amaria, RN, Thomas, AS. Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Thomas AS, Abreo M, Ahmed AS, Manikonda SP, Eyada M, Issac A, Abraham F, Jacob JS, Wang Y, Yedururi S, Chari SG. Immune Checkpoint Inhibitor-Induces Pancreatic Injury: Clinical and Radiological Profile and Response to Steroids. Gastro Hep Advances 3(3):361-367, 2023. e-Pub 2023.
- Sperling G, Shatila M, Varatharajalu K, Lu Y, Altan M, Zhou Y, Zhao D, De Toni EN, Török HP, Schneider BJ, Khan A, Thomas AS, Zhang HC, Shafi MA, Wang Y. Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors. J Cancer Res Clin Oncol 149(19):17597-17605, 2023. e-Pub 2023. PMID: 37917197.
- Thomas AS, Chari ST. Immune Checkpoint Inhibitor-Induces (Type 3) Autoimmune Pancreatitis. Curr Gastroenterol Rep 25(10):255-259, 2023. e-Pub 2023. PMID: 37845557.
- Thomas AS, Lee SE, Shatila M, De Toni EN, Torok HP, Khaled B, Powell N, Weight R, Faleck DM, Wang Y. IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience. Am J Gastroenterol 118(9):1679-1683, 2023. e-Pub 2023. PMID: 37216614.
- Kuang AG, Sperling G, Liang TZ, Lu Y, Tan D, Bollin K, Johnson DB, Manzano JM, Shatila M, Thomas AS, Thompson JA, Zhang HC, Wang Y. Sclerosing Mesenteritis Following Immune Checkpoint Inhibitor Therapy. J Cancer Res Clin Oncol 149(11):9221-9227, 2023. e-Pub 2023. PMID: 37195298.
- Machado AP, Shatila M, Liu C, Wang J, Altan M, Zhang HC, Thomas AS, Wang Y. Immune-Related Adverse Events After Immune Checkpoint Inhibitor Exposure in Adult Cancer Patients with Pre-Existing Autoimmune Diseases. J Cancer Res Clin Oncol 149(9):6341-6350, 2023. e-Pub 2023. PMID: 36752908.
- Machado AP, Shatila M, Glitza Oliva IC, Altan M, Siddiqui B, Zhou Y, Varatharajalu K, Zhang HC, Thomas AS, Wang Y. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Am J Clin Oncol 46(8):360-365, 2023. e-Pub 2023. PMID: 37219360.
- Shatila M, Ma W, Cui Y, Naz S, Thomas AS, DeToni EN, Torok HP, Khaled NB, Altan M, Schneider B, Wang Y. Effects of Immunosuppressive Treatment on Patient Outcomes After Immune Checkpoint Inhibitor-Related Gastrointestinal Toxicity. J Cancer Res Clin Oncol 149(10):7793-7803, 2023. e-Pub 2023. PMID: 37029815.
- Machado AP, Shatila M, Liu C, Lu Y, Altan M, Glitza Oliva IC, Zhao D, Zhang HC, Thomas AS, Wang Y. Characteristics, Treatment, and Outcome of Patients with Bowel Perforation After Immune Checkpoint Inhibitor Exposure. J Cancer Res Clin Oncol 149(9):5989-5998, 2023. e-Pub 2023. PMID: 36611109.
- Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas AS. Implementing an Immunotherapy Toxicity (IOTOX) GI Service Improves Outcomes in Patients with Immune-Mediated Diarrhea and Colitis. J Cancer Res Clin Oncol 149(9):5841-5852, 2023. e-Pub 2023. PMID: 36585982.
- Mathew A, Shatila M, Lai Z, Tan D, Glitza Oliva IC, Wang J, Alhalabi O, Zhang HC, Thomas AS, Wang Y. Characteristics of Appendicitis After Immune Checkpoint Inhibitor Therapy Among Cancer Patients. J Cancer Res Clin Oncol 149(8):4591-4599, 2023. e-Pub 2023. PMID: 36163559.
- Hollander B, Khurana S, Jacob JS, Altan M, Wang J, Zhao D, Varatharajalu K, Alasadi M, Thomas AS, Wang Y. Mesalamine and Cholestyramine for Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis. J Cancer Res Clin Oncol 149(7):3637-3648, 2023. e-Pub 2023. PMID: 35972690.
- Thomas AR, Liu C, Tong YT, Tan D, Altan M, Siddiqui BA, Shatila M, Khan A, Thomas AS, Wang Y. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. J Cancer Res Clin Oncol 149(8):5429-5436, 2023. e-Pub 2023. PMID: 36451045.
- Thomas AR, Eyada M, Kono M, Varatharajalu K, Lu Y, Xu G, Panneerselvam K, Shatila M, Altan M, Wang J, Thompson JA, Zhang HC, Khan MA, Raju GS, Thomas AS, Wang Y. Characteristics, Treatment, and Outcome of Diverticulitis After Immune Checkpoint Inhibitor Treatment in Patients with Malignancies. J Cancer Res Clin Oncol 149(8):4805-4816, 2023. e-Pub 2023. PMID: 36242603.
- Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Tyrosine Kinase Inhibitor-Related Lower GI Adverse Effects. J Cancer Res Clin Oncol 149(7):3965-3976, 2023. e-Pub 2023. PMID: 36030431.
- Halsey TM, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, Parra ER, Jiang ZD, DuPont HL, Sanchez C, El-Himri R, Brown A, Flores I, McDaniel L, Ortega Turrubiates M, Hensel M, Pham D, Watowich SS, Hayase E, Chang CC, Jenq RR, Wang Y. Microbiome Alteration via Fecal Microbiota Transplantation is Effective for Refractory Immune Checkpoint Inhibitor-Induced Colitis. Sci Transl Med 15(700):eabq4006, 2023. e-Pub 2023. PMID: 37315113.
- Abu-Sbeih H, Tang T, Ali FS, Ma W, Shatila M, Luo W, Tan D, Tang C, Richards DM, Ge PS, Thomas AS, Wang Y. Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy. Cancers (Basel) 12(15(12)):3160, 2023. e-Pub 2023. PMID: 37370770.
- Badran YR, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, Altan M, Thompson JA, Qiao W, Leet DE, Lai PY, Horick NK, Postow MA, Faleck DM, Wang Y, Dougan M. Concurrent Immune Checkpoint Inhibition and Selective Immunosuppressive Therapy in Patients with Immune-Related Enterocolitis. J Immunother Cancer 11(6):e007195, 2023. e-Pub 2023. PMID: 37349130.
- Kono, M, Shatila, M, Xu, G, Lu, Y, Mathew, A, Mohajir, W, Varatharajalu, K, Qiao, W, Thomas, AS, Wang, Y. Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis. Cancers 15(8), 2023. e-Pub 2023. PMID: 37190257.
- Thomas AS, Hanauer S, Wang Y. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 21(4):878-890, 2023. e-Pub 2023. PMID: 36270617.
- Dutra B, Garcia-Rodriguez V, Garcia R, Szafron D, Abraham F, Khurana S, Lockhart J, Amin R, Wang Y, Thomas AS. Characteristics and Outcomes of Cancer Patients with Venous Thromboembolic Events After Treatment with Immune Checkpoint Inhibitors. Am J Clin Oncol 46(3):94-100, 2023. e-Pub 2023. PMID: 36735530.
- Liu, C, Shatila, M, Mathew, A, Machado, AP, Thomas, A, Zhang, HC, Thomas, AS, Faleck, DM, Funchain, P, Philpott, J, Grivas, PD, Obeid, M, Carbonnel, F, Wang, Y. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. Journal of Cancer 14(10):1913-1919, 2023. e-Pub 2023.
- Thomas AS, Abreo M, Sayed SA, Sireesha Yedururi YW, Chari ST. Autoimmune Pancreatitis Secondary to Immune Checkpoint Inhibitor Therapy (Type 3 AIP): Insights Into a New Disease From Serial Pancreatic Imaging. Gastroenterology 164(1):154-155, 2023. e-Pub 2023. PMID: 36220459.
- Kuang AG, Mohajir W, Panneerselvam K, McQuade JL, Oliva ICG, Khan MA, Zhang HC, Thomas AS, Wang Y. Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. Ann Gastroenterol 36(1):45-53, 2023. e-Pub 2023. PMID: 36593813.
- Thomas AS, Takahashi N, Levy MJ, Abraham SC, Del Castillo CF, Chari ST. Picking a Zebra Among Horses: More Difficult Than You Think!. Gastroenterology 164(1):34-41, 2023. e-Pub 2023. PMID: 36332667.
- Liu C, Shatila M, Mathew A, Machado AP, Thomas A, Zhang HC, Thomas AS, Faleck D, Funchain P, Philpott J, Grivas P, Obeid M, Carbonnel F, Wang Y. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. J Cancer 14(10):1913-1919, 2023. e-Pub 2023. PMID: 37476185.
- Machado AP, Shatila M, De Toni EN, Török HP, Philpott J, Zhao D, Zhou Y, Varatharajalu K, Shafi MA, Zhang HC, Thomas AS, Wang Y. Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis. J Cancer 14(14):2686-2693, 2023. e-Pub 2023. PMID: 37779873.
- Amin, R, Thomas, AS, Wang, Y. Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption. Annals of Internal Medicine Clinical Cases 1(10), 2022. e-Pub 2022.
- Amin R, Thomas AS, Wang Y. Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption. Annals of Internal Medicine: Clinical Cases 1(10):e220490, 2022. e-Pub 2022.
- Shmed AS, Abreo M, Thomas AS, Chari ST. Type 3 Autoimmune Pancreatitis (Immune Checkpoint Inhibitor-Induces Pancreatitis). Curr Opin Gastroenterol 38(5):516-520, 2022. e-Pub 2022. PMID: 35881977.
- Yu K, Mathew A, Abraham F, Amin R, Kono M, Overman M, Zhao D, Khan A, Khan MA, Thomas AS, Wang Y. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Ann Gastroenterol 35(5):514-521, 2022. e-Pub 2022. PMID: 36061157.
- Panneerselvam K, Szafron D, Amin RN, Wei D, Tan D, Altan M, Okhuysen PC, Shatila M, Raju GS, Thomas AS, Wang Y. Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors. Ann Gastroenterol 35(5):522-531, 2022. e-Pub 2022. PMID: 36061160.
- Vasavada S, Panneerselvam K, Amin R, Varatharajalu K, Okhuysen PC, Oliva ICG, Wang J, Grivas P, Thomas AS, Wang Y. Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors. Ann Gastroenterol 35(4):393-399, 2022. e-Pub 2022. PMID: 35784625.
- Thomas AS, Huang Y, Kwon W, Schrope BA, Sugahara K, Chabot JA, Wright JD, Kluger MD. Prevalence and Risk Factors for Pancreatic Insufficiency After Partial Pancreatectomy. J Gastrointest Surg. e-Pub 2022. PMID: 35318597.
- Dutra BES, Wei D, Tan D, Alasadi M, Zhang HC, Thomas A, Thomas AS, Richards DM, Wang Y. Clinical Characteristics and Outcomes of Patients with Positive Celiac Serology and Cancer Therapy Exposure. J Cancer 13(3):815-822, 2022. e-Pub 2022. PMID: 35154450.
- Zou F, Faleck DM, Thomas AS, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer SB, McQuade JL, Obeid M, Shah AY, Richards DM, Sharon E, Wolchok J, Thompson JA, Wang Y. Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-mediated Diarrhea and Colitis in Cancer Patients: a two-center observational study. J Immunother Cancer 9(11):e003277, 2021. e-Pub 2021. PMID: 34789551.
- Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and Efficacy of Fecal Microbiota Transplantation to Treat and Prevent Recurrent Clostridioides Difficile in Cancer Patients. J Cancer 12(21):6498-6506, 2021. e-Pub 2021. PMID: 34659541.
- Khurana S, Abu-Sbeih H, Ma W, Qiao W, Foo WC, Richards DM, Thomas AS, Khan A, Zhang HC, Wang Y. Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. Am J Clin Oncol 44(8):395-401, 2021. e-Pub 2021. PMID: 34091476.
- Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen PC, McQuade JL, Altan M, Zhang HC, Thomas AS, Wang Y. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. Am J Clin Oncol 44(8):402-408, 2021. e-Pub 2021. PMID: 34107499.
- Jacob JS, Dutra BE, Garcia-Rodgriguez V, Panneerselvam K, Abraham FO, Zou F, MA W, Grivas P, Thompson JA, Altan M, Glitza IC, Zhang HC, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Oral Mucositis Associated with Immune Checkpoint Inhibitors in Patients with Cancer. J Natl Compr Canc Netw 4(19(12)):1415-1424, 2021. e-Pub 2021. PMID: 34348238.
- Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, Charabaty A, Okhuysen P, McQuade J, Altan M, Zhang HC, Thomas AS, Wang Y. Outcomes of Immune Checkpoint Inhibitor-Related Diarrhea or Colitis in Cancer Patients with Superimposed Gastrointestinal Infections. Am J Clin Oncol 44(8):402-408, 2021. e-Pub 2021. PMID: 34107499.
- Panneerselvam K, Amin RN, Wei D, Tan D, Lum PJ, Zhang HC, Richards DM, Altan M, Grivas P, Thompson JA, Thomas AS, Wang Y. Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. J Natl Compr Canc Netw 19(8):896-904, 2021. e-Pub 2021. PMID: 34102607.
- Thomas AS, Criss ZK, Shroyer NF, Abraham BP. Vitamin D Receptor Gene Single Nucleotide Polymorphisms and Association with Vitamin D Levels and Endoscopic Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Study. Inflamm Bowel Dis 27(8):1263-1269, 2021. e-Pub 2021. PMID: 33165606.
- Thomas AS, Ma W, Wang Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N Engl J Med 384(6):581-583, 2021. e-Pub 2021. PMID: 33567198.
- Panneerselvam K, Goyal S, Thomas AS. Ileo-Colonic Lymphoma: Presentation, Diagnosis, and Management. Curr Opin Gastroenterol 37(1):52-58, 2021. e-Pub 2021. PMID: 33105251.
- Zhou F, Wang X, Glitza IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal Calprotectin Concentration to Assess Endoscopic and Histologic Remission in Patients with Cancer with Immune-Mediated Diarrhea and Colitis. J Immunother Cancer 9(1):e002058, 2021. e-Pub 2021. PMID: 33436487.
- Thomas AS, Wang Y. Immunotherapy-Mediated Luminal Gastrointestinal Toxicities. Adv Exp Med Biol 1342:331-337, 2021. e-Pub 2021. PMID: 34972972.
- Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza Oliva IC, Piha-Paul SA, Thompson JA, Zhang HC, Thomas AS, Wang Y. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. J Natl Compr Canc Netw 19(6):700-708, 2020. e-Pub 2020. PMID: 33316767.
- Shirwaikar Thomas A, Duran A, Abraham BP. Correlation of Menstrual Distress to Severity of Gastrointestinal Symptoms in Inflammatory Bowel Disease Patients. Indian J Gastroenterol 39(5):514-520, 2020. e-Pub 2020. PMID: 32960406.
- Amin R, Thomas AS, Khurana S, Panneerselvam K, Zou F, Ma W, Chari ST, Wang Y. Management of Immune-Related Colitis During the COVID-19 Pandemic. Inflamm Bowel Dis 26(10):e110-e111, 2020. e-Pub 2020. PMID: 32812047.
- Peng Y, Thomas AS, Wei D, Tan D, Wang Y. An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia. Inflamm Bowel Dis 26(4):e26-e27, 2020. e-Pub 2020. PMID: 32016290.
- Thomas AS, Ro JY, Ergun GA. "Doctor, I Just Can't Seem to Swallow!". Gastroenterology 157(4):938-939, 2019. e-Pub 2019. PMID: 31158370.
- Shirwaikar Thomas A, Schwartz M, Quigley E. Gastrointestinal lymphoma: the new mimic. BMJ Open Gastroenterol 6(1):e000320, 2019. e-Pub 2019. PMID: 31645987.
- Thomas AS, Schwartz MR, Neshatian L. A Rare Cause of an Upper Gastrointestinal Bleed. Gastroenterology 155(1):e3-e4, 2018. e-Pub 2018. PMID: 29102618.
- Thomas AS, Estep J, Victor DW. Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding in a Patient with a Left Ventricular Assist Device. ACG Case Rep J 5:e11, 2018. e-Pub 2018. PMID: 29430470.
- Thomas AS, Perez JA. Complications of Varicella Zoster Infection of the Central Nervous System. Methodist Debakey Cardiovasc J 13(2):76-77, 2017. e-Pub 2017. PMID: 28740587.
- Aderinto-Adike A, Hannawi B, Thomas AS, Nowbakht C, Varon J. Painful skin lesions and bloody diarrhea. Crit Care and Shock(18):3-4, 2015. e-Pub 2015.
- Schutt RC, Bibawy J, Elnemr M, Lehnert AL, Putney D, Thomas AS, Barker CM, Pratt CM. Case report: Severe hypercalcemia mimicking ST-segment elevation myocardial infarction. Methodist Debakey Cardiovasc J 10(3):193-7, 2014. e-Pub 2014. PMID: 25574349.
- Thomas AS, Varughese P, Shirwaikar A, Shirwaikar A. Herb - Drug Interactions: A Review. Hygeia - Journal for Drugs & Medicines(4):2, 2012. e-Pub 2012.
Review Articles
- Moura MJ, Chatterjee A, Wali S, Garza DR, Salim H, Rong J, Menon R, Jafri F, Urias Rivera A, Mortan R, Palaskas NL, Reynolds KL, Leaf RK, Kikani N, Thomas A, Zhang HC, Wang LS, Tummala S, Al-Zubidi N, Sheshadri A, Abudayyeh A, Jeff YL, Wang Y. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review. Expert Opin Drug Saf:1-14, 2026. e-Pub 2026. PMID: 41995025.
- Rong J, Jafri F, Ngo S, Chatterjee A, Moura Nascimento Santos MJ, Garza D, Salim H, Menon R, Mortan R, Urias Rivera AC, Zhang HC, Patel A, Rojas Hernandez C, Jeff Li Y, Sheshadri A, Aaroe A, Shariff A, Schneider B, Thomas A, Wang Y. Rare irAEs associated with immune checkpoint inhibitor therapy. Expert Opin Drug Saf:1-15, 2026. e-Pub 2026. PMID: 41664562.
- Vemulapalli V, Natha C, Shirwaikar Thomas A. Autoimmune Pancreatitis: A Review. J Clin Med 14(9), 2025. e-Pub 2025. PMID: 40364113.
- Zaher A, Moura Nascimento Santos MJ, Elsaygh H, Peterson SJ, Colli Cruz C, Thomas AS, Wang Y. Management of refractory checkpoint inhibitor-induced colitis. Expert Opin Drug Saf 25(1):1-10, 2025. e-Pub 2025. PMID: 40251944.
- Vemulapalli V, Shirwaikar Thomas A. The Role of Vitamin D in Gastrointestinal Homeostasis and Gut Inflammation. Int J Mol Sci 26(7), 2025. e-Pub 2025. PMID: 40243631.
- Colli Cruz C, Moura Nascimento Santos MJ, Wali S, Varatharajalu K, Thomas AS, Wang Y. Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management. Immunotherapy 17(4):293-303, 2025. e-Pub 2025. PMID: 40055892.
- Wang, Y, Shah, JS, Urias Rivera, AC, Mathew, A, Thomas, AS, Altan, M, Zhao, D. Effect of PD-1/ PD-L1 and statin combination therapy on gastrointestinal toxicity related to immune checkpoint inhibitors and on survival. Journal of Clinical Oncology 42:742, 2024. e-Pub 2024.
- Machado AP, Ratliff H, Abdelwahab A, Vohra MH, Kuang A, Shatila M, Khan MA, Shafi MA, Thomas AS, Philpott J, Alhalabi O, Wang Y. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review. J Cancer 14(16):2956-2963, 2023. e-Pub 2023. PMID: 37859810.
- Shatila M, Thomas AS. Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. J Clin Med 11(17), 2022. e-Pub 2022. PMID: 36079015.
- Thomas AS, Quigley EM. Diet and irritable bowel syndrome. Curr Opin Gastroenterol 31(2):166-71, 2015. e-Pub 2015. PMID: 25612261.
Other Articles
- Vemulapalli V, Thomas AS The Role of Vitamin D in Gastrointestinal Homeostasis and Gut Inflammation. International Journal of Molecular Sciences, 2025.
- Thomas, AS, Lu, Y, Campbell, M, Thompson, JA, Tan, D, Faleck, DM, Wang, Y Immune Checkpoint Inhibitor–Induced Colitis. Gastroenterology 168(1):21-28, 2025. PMID: 39389184.
Editorials
- Rockey, DC, Thomas, AS. Editorial introductions. Current opinion in gastroenterology 42(1):v, 2026.
Abstracts
- Shatila M, Cruz CC, Varatharajalu K, Urias Rivera AC, Abdul-Baki K, Takigawa K, Gupta T, Baerman E, Lu L, Lee IJ, Salim H, Menon R, Sullivan A, Vemulapalli V, Natha C, Khan A, Grivas P, Faleck D, Dougan M, Thomas AS, Wang Y. Validation of the Immune-Mediated Colitis Endoscopic Score using a Retrospective Cohort of Patients with Immune-Mediated Colitis. e-Pub 2025.
- Wang Y, Varatharajalu K, Shatila M, Thomas AS, Campbell M, Msaouel P, Kovitz C, DuPont H. First-Line Treatment of Fecal Microbiota Transplantation for Immune-Mediated Colitis. The American Journal of Gastroenterology 118(10S):S170, 2023. e-Pub 2023.
- Wang Y, Varatharajalu K, Shatila M, Shen SE, Herrera M, Letona E, Wany XS, Thomas AS, Jiang ZD, DuPont H. Fecal Transplantation Improved Patients' Reported Outcome after Immune Checkpoint Inhibitor Colitis. The American Journal of Gastroenterology 118(10S):S170-S171, 2023. e-Pub 2023.
- Shatila M, Machado AP, Shah JS, Naz S, Short N, Thomas AS, Zhang HC, Wang Y. The Interplay Between Immunocompromise and Immunotherapy Affects the Risk of Inflammatory Adverse Events. The American Journal of Gastroenterology 118(10S):S183-S184, 2023. e-Pub 2023.
- Shatila M, Eshaghi F, Thomas A, Kuang A, Naz S, Zhao B, Thomas AS, Zhang HC, Wang Y. Practice Changes in Management of Gastrointestinal Immune-Related Adverse Events at a Tertiary Care Cancer Center. The American Journal of Gastroenterology 118(10S):S184-S185, 2023. e-Pub 2023.
- Shah JS, Devalaraju SS, Baerman E, Shatila M, Machado AP, Catinis C, Thomas AS, Wang Y. Gastrointestinal Toxicities of Proteasome Inhibitor Therapy. The American Journal of Gastroenterology 118(10S):S193, 2023. e-Pub 2023.
- Kuang A, Shah JS, Mittal N, Shatila M, Naz S, Iyer S, Thomas AS, Zhang HC, Wang Y. Gastrointestinal Adverse Events Following Brentuximab Vedotin and Polatuzumab Vedotin Therapy. The American Journal of Gastroenterology 118(10S):S203, 2023. e-Pub 2023.
- Machado AP, Wang Y, Thomas AS. Immune Checkpoint Inhititor-Associated Gastrointestinal Adverse Events in Patients with Colorectal Cancer. The American Journal of Gastroenterology 118(10S):S138, 2023. e-Pub 2023.
- Machado AP, Saji A, Shaikh AS, Wang Y, Thomas AS. Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor Related Colitis in Patients with Cancer. The American Journal of Gastroenterology 118(10S):S649-S650, 2023. e-Pub 2023.
- Silva NN, Wang Y, Thomas AS. Therapeutic Drug Monitoring of Vedolizumab in Management of Immune Checkpoint Inhibitor-Mediated Colitis. The American Journal of Gastroenterology 118(10S):S2149-S2150, 2023. e-Pub 2023.
- Machado AP, Afifi AM, Tatliff H, Vohra MH, Kuang A, Shatila M, Khan MA, Thomas AS, Philpott J, Alhalabi O, Wang Y. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology 118(10S):S1266-S1267, 2023. e-Pub 2023.
- Shah JS, Rivera AU, Mathew A, Thomas AS, Zhang HC, Altan M, Zhao D, Wang Y. Effect of PD-1/PD-L1 and Statin Combination Therapy on Gastrointestinal Toxicity Related to Immune Checkpoint Inhibitors and on Survival. The American Journal of Gastroenterology 118(10S):S1322, 2023. e-Pub 2023.
- Shatila M, Sperling G, Vohra MH, Machado AP, Thomas AS, Al-Asadi M, Wang Y. Helicobacter pylori Seropositivity is Associated with Worse Outcomes Among Patients on Immunotherapy for Gastric Cancer. The American Journal of Gastroenterology 118(10S):S1403-S1404, 2023. e-Pub 2023.
- Mittal N, Shatila M, Naz S, Lu Y, Thomas AS, Zhang HC, Iyer PC, Hu MI, Wang Y. Similar Features of PET Scan in Gastrointestinal Tract Related to Metformin and Immune Related Enterocolitis. The American Journal of Gastroenterology 118(10S):S221, 2023. e-Pub 2023.
- Abreo M, Eyada M, Issac AG, Abraham F, Jacob JS, Wang Y, Chari S, Yedururi S, Thomas AS. Immune Checkpoint Inhibitor-Induced (Type 3) Autoimmune Pancreatitis: Clinical Profile and Natural History Based on Serial Pancreas Volumetry. Digestive Disease Week 2022. e-Pub 2022.
- Thomas AS, Yedururi S, Eyada M, Wang Y, Chari S. Symptomatic Type 3 auto- immune pancreatitis/immune checkpoint inhibitor pancreas injury (ICI-PI) leads to chronic pancreatic injury. APA 2021 Annual Meeting, 2021. e-Pub 2021.
- Thomas AS, Halsey T, Jiang ZD, DuPont H, Jenq R, Wang Y. Microbiome Alteration via Fecal Microbiota Transplantation (FMT) Is Effective for Immune Checkpoint Inhibitor (ICI) Induced-Colitis (IMC) Refractory to Immunosuppressive Therapy. ACG 2021, 2021. e-Pub 2021.
- Kuang, A, Mohajir W, Thomas AS, Wang Y. Diarrhea and Colitis Related to Immune Checkpoint Inhibitor and BRAF/MEK Inhibitor Therapy. ACG 2021 Annual Meeting, 2021. e-Pub 2021.
- Thomas AS, McQuade J, Altan M, Wang Y. IL12/23 Blockade Therapy for Refractory Immune Checkpoint Inhibitor Colitis: A Case Series. ACG 2021, 2021. e-Pub 2021.
- Zou F, Dutra B, Wang X, Glitza-Oliva IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with immune-mediated diarrhea and colitis. Digestive Disease Week 2021, 2021. e-Pub 2021.
- Zou F, Faleck DM, Thomas AS, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer SB, McQuade JL, Obeid M, Shah AY, Richards DM, Sharon E, Wolchok J, Thompson JA, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in cancer patients: a multi-center study. DDW 2021, 2021. e-Pub 2021.
- Yu KK, Abraham F, Thomas AS, Wang Y. Incidence of Immune Checkpoint Inhibitor Related GI Toxicity in Patients with GI Luminal Malignancy and Outcomes after Treatment. DDW 2021, 2021. e-Pub 2021.
- Panneerselvam K, Szafron D, Amin R, Khurana S, Wei D, Tan D, Okhuysen P, Zhang HC, Thomas AS, Wang Y. Characteristics, treatment, and outcomes of CMV infection in patients treated with immune checkpoint inhibitors. DDW 2021, 2021. e-Pub 2021.
- Vasavada S, Amin RN, Okhuysen P, Thomas AS, Wang Y. Clostridioides Difficile infections in cancer patients on immune checkpoint inhibitors. DDW 2021, 2021. e-Pub 2021.
- Zou F, Thomas AS, Dutra B, Khurana S, Abu-Sbeih H, Altan M, McQuade J, Thompson JA, Wang Y. Immune checkpoint inhibitor resumption is associated with better long term outcome in cancer patients. DDW 2021, 2021. e-Pub 2021.
- Zou F, Thomas AS, Dutra B, Khurana S, Abu-Sbeih H, Altan M, McQuade J, Thompson JA, Wang Y. Maintenance therapy reduces recurrence of immune-mediated colitis after resumption of immunotherapy in cancer patients. DDW 2021, 2021. e-Pub 2021.
- Dutra B, Wei D, Tan D, Thomas AS, Richards D, Wang Y. Clinical characteristics and outcomes of patients with positive celiac serology and cancer therapy exposure. DDW 2021, 2021. e-Pub 2021.
- Thomas AS, Wang Y. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol 115(8):1301-1302, 2020. e-Pub 2020. PMID: 32756260.
- Thomas AS, Oglat A, Granillo A, Duran A, Abraham B. The Association of Vitamin D and Endoscopic Disease Severity in Patients with Inflammatory Bowel Disease. American College of Gastroenterology 2018, 2018. e-Pub 2018.
- Thomas AS, Quigley EM, Ondo W. Plecanatide for Constipation Associated with Parkinson’s Disease: A Case Series. American College of Gastroenterology 2018, 2018. e-Pub 2018.
- Thomas AS, Kwon MC, Granillo A, Quigley EM, Ergun GA. Esophagogastric junction outflow obstruction – features, etiology and outcome in a single center experience. Time for standardization?. American College of Gastroenterology 2018, 2018. e-Pub 2018.
- Thomas AS, McFadden R. Double Trouble: Chronic Hepatitis C and Hepatocellular Carcinoma. American College of Gastroenterology 2018, 2018. e-Pub 2018.
- Thomas AS, Oglat A, Araujo-Gutierrez R, Nguyen DT, Graviss EA, Trachtenberg B, Victor D. Gastrointestinal Amyloidosis Does Not Impact Rejection Burden After Orthoptic Heart Transplant: A Retrospective Study. American College of Gastroenterology 2018, 2018. e-Pub 2018.
- Thomas AS, Fosso C, Neshatian L. Relationship between anal pressure profiles derived from high-definition anorectal manometry and results of balloon expulsion test in patients with chronic constipation. Digestive Disease Week 2017, 2017. e-Pub 2017.
- Thomas A, Fosso C, Abraham BP. Correlation of Menstrual Distress to the severity of Gastrointestinal Symptoms in inflammatory bowel disease patients. American College of Gastroenterology 2017, 2017. e-Pub 2017.
- Thomas AS, Divatia M, Olano J, Schwartz M, McFadden R. Murine Typhus-related Acute febrile Hepatitis:A case series. American College of Gastroenterology 2017, 2017. e-Pub 2017.
- Thomas AS, Ewton A, Schwartz M, Quigley E. Gastrointestinal Lymphoma: A case series illustrating its varied presentation and the role of the gastroenterologist in its assessment. American College of Gastroenterology 2017, 2017. e-Pub 2017.
- Thomas AS, Elnemr M, Abraham BP. Primary Gastrointestinal Histoplasmosis and Vedolizumab. American College of Gastroenterology 2016, 2016. e-Pub 2016.
- Thomas AS, Barroso A, Schwartz M, Raza A. Benign Squamous Cyst Within An Intra- Pancreatic Spleen : A Case Report. American College of Gastroenterology 2015, 2015. e-Pub 2015.
- Thomas AS. Something Fishy. ACP Associates Day 2015, 2015. e-Pub 2015.
- Thomas AS, Ogbonna M, Gilcrease-Garcia B. A stroke of the Kidney. ACP Associates Day 2015, 2015. e-Pub 2015.
- Thomas AS, Bunin V, Powell S. Autoimmune Hepatitis With Primary Sclerosing Cholangitis and Co-Existent Necrotizing Myopathy: A Rare Association. American College of Gastroenterology 2015, 2015. e-Pub 2015.
- Thomas AS, Charikriangkai K, Chang S, Botero S. Hepatic steatosis is independently associated with coronary atherosclerosis. American College of Gastroenterology 2014, 2014. e-Pub 2014.
- Adigun R, Jhun HY, Thomas AS, Tompson M. An unexpected diagnosis of tuberculosis colitis. American College of Gastroenterology 2014, 2014. e-Pub 2014.
- Thomas AS. Fecal microbiota transplant (FMT) for immune checkpoint inhibitor (ICI) induced–colitis (IMC) refractory to immunosuppressive therapy. ACG 2020.
- Zou F, Abu-Sbeih H, Ma W, Peng Y, Qiao W, Wang J, Shah AY, Glitza IC, Piha-Paul S, Thompson JA, Zhang HC, Thomas AS, Wang Y. Chronic Immune-mediated Diarrhea and Colitis Is Associated with Favorable Cancer Response. ACG 2020.
- Thomas AS. Comparison of Clinical Profiles, Treatment and Outcomes of Type 1 and Type 2 Autoimmune Pancreatitis (AIP) With Immune Checkpoint Inhibitor Pancreatitis, a Type 3 AIP. APA 2020 Annual Meeting.
- Panneerselvam K, Amin RN, Wei D, Tan D, Lum PJ, Zhang HC, Richards DM, Altan M, Grivas P, Thompson JA, Thomas AS, Wang Y. Clinicopathological features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis. ACG 2020.
- Jacob JS, Dutra BE, Garcia-Rodgriguez V, Panneerselvam K, Abraham FO, Zou F, MA W, Grivas P, Thompson JA, Altan M, Glitza IC, Zhang HC, Thomas AS, Wang Y. Clinical Characteristics and Outcomes of Oral Mucositis Associated with Immune Checkpoint Inhibitors in Patients with Cancer. ACG 2020.
- Thomas AS. Comparative Study of Vedolizumab and Infliximab Treatment in Patients with Immune-mediated Diarrhea and Colitis. ACG 2020.
Book Chapters
- Shatila M, Varatharajalu K, Raju GS, Thomas AS, Wang Y. Cholecystitis Related to Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities [Internet] Switzerland AG 2025. Springer Cham, p.95-101, 2025.
- Shatila, M, Varatharajalu, K, Raju, GS, Thomas, AS, Wang, Y. Cholecystitis Related to Immune Checkpoint Inhibitor Therapy, 95-101, 2025.
- Naz, S, Thomas, AS, Wang, Y, Lu, Y. Enteritis and Venous Thromboembolism Related to Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities [Internet] Switzerland AG 2025. Springer Cham, 125-129, 2025.
- Shatila, M, Varatharajalu, K, Shafi, MA, Thomas, AS, Wang, Y. Upper Gastrointestinal Toxicity Following Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities [Internet] Switzerland AG 2025. Springer Cham, 179-185, 2025.
- Naz, S, Wang, Y, Chari, ST, Thomas, AS, Yedururi, S. Necrotizing Pancreatitis Related to Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities [Internet] Switzerland AG 2025. Springer Cham, 369-374, 2025.
- Shatila, M, Varatharajalu, K, Thomas, AS, Wang, Y, DuPont, HL, Jenq, RR, Carbonnel, F, Hanauer, S. Colitis Following Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities [Internet], 103-111, 2025.
- Naz, S, Wang, Y, Chari, ST, Thomas, AS, Yedururi, S. Pancreatitis Related to Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities [Internet] Switzerland AG 2025. Springer Cham, 361-367, 2025.
- Thomas, AS, Wang, Y. Gastroenterology (GI), 81-96, 2022.
- Thomas, AS, Zhang, HC, Wang, Y, Chari, ST. Pancreas and Gallbladder, 255-264, 2022.
- Thomas AS, Zhang HC, Wang Y, Chari ST. Pancreas and Gallbladder. In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. 1. Springer Cham, 255-264, 2022.
- Thomas AS, Wang Y. Immunotherapy-Mediated Luminal Gastrointestinal Toxicities. In: Immunotherapy. Advances in Experimental Medicine and Biology. Springer, Cham, 331-337, 2022.
- Thomas AS, Wang Y. Gastroenterology (GI). In: Managing Immunotherapy Related Organ Toxicities: A Practical Guide. 1. Springer Cham, 81-96, 2022.
- Thomas AS, Quigley EM, Ford AC. Gut Microbiota in Functional Bowel Disorders. In: WGO Handbook on Gut Microbiome: A Global Perspective, 34-40, 2021.
Letters to the Editor
- Thomas AS, Ma W, Wang Y. Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N Engl J Med 384: 581-583, 2021.
Patient Reviews
CV information above last modified August 18, 2026